Intraperitoneal chemotherapy in the management of pancreatic adenocarcinoma: A systematic review and meta-analysis
- PMID: 35688711
- DOI: 10.1016/j.ejso.2022.05.030
Intraperitoneal chemotherapy in the management of pancreatic adenocarcinoma: A systematic review and meta-analysis
Abstract
Background: Pancreatic cancer represents one of the leading causes of cancer-related death worldwide. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC), normothermic intraperitoneal chemotherapy (NIPEC), and pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been proven with curative intent mainly for other tumors and there is a lack of consensus regarding possible benefits also in pancreatic cancer. The present systematic review and meta-analysis aim to provide an up-to-date overview of the effectiveness and safety of intraperitoneal treatments in the management of pancreatic cancer.
Methods: A systematic review of articles was conducted according to PRISMA and AMSTAR-2 guidelines. 11 studies were included in the analysis.
Results: We included in our analysis 212 patients subdivided in three groups: 64 in the HIPEC group (57 with prophylactic intent and 7 with curative intent), 55 in the PIPAC group and 93 in the NIPEC group. Primary outcomes were represented by survival rates; we evidenced at an observation time of three years a survival of 24% in the HIPEC group (25.5% in the prophylactic arm and 6.2% in the curative arm), 5.3% in the PIPAC group and 7.9% in the NIPEC group.
Conclusions: HIPEC could be considered as a promising technique for prophylaxis and treatment of peritoneal metastasis (PM) in case of borderline resectable and locally advanced disease. Increased survival rates emerged without additional morbidity when surgical resection and CRS are possible. In addition, our data about PIPAC and NIPEC as palliative treatment in unresectable disease seems to identify more favorable survival rates compared to literature.
Keywords: Hyperthermic IntraPeritoneal chemotherapy; Intraperitoneal chemotherapy; Meta-analysis; Normothermic IntraPeritoneal chemotherapy; Pancreatic adenocarcinoma; Pancreatic cancer; Pressurized IntraPeritoneal aerosol chemotherapy; Systematic review.
Copyright © 2022 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no conflict of interest.
Similar articles
-
Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and meta-analysis of observational studies.Cancer Treat Rev. 2013 Jun;39(4):321-7. doi: 10.1016/j.ctrv.2012.11.003. Epub 2012 Dec 12. Cancer Treat Rev. 2013. PMID: 23244778
-
The role of complete cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in ovarian carcinoma: where do we stand today? A comprehensive review and clinical insights from a leading oncology center in India.World J Surg Oncol. 2025 Jun 11;23(1):232. doi: 10.1186/s12957-025-03869-0. World J Surg Oncol. 2025. PMID: 40500703 Free PMC article. Review.
-
Heated IntraPEritoneal Chemotherapy (HIPEC) for Patients With Recurrent Ovarian Cancer: A Systematic Literature Review.Int J Gynecol Cancer. 2016 May;26(4):661-70. doi: 10.1097/IGC.0000000000000664. Int J Gynecol Cancer. 2016. PMID: 26844612
-
Prophylaxis and treatment of peritoneal carcinomatosis of gastric origin using hyperthermic intraperitoneal chemotherapy: a systematic review and meta-analysis of randomized trials.J Gastrointest Surg. 2024 Jul;28(7):1185-1193. doi: 10.1016/j.gassur.2024.04.007. Epub 2024 Apr 8. J Gastrointest Surg. 2024. PMID: 38599315
-
A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for Appendiceal and Colorectal Adenocarcinoma with Peritoneal Metastasis.Ann Surg Oncol. 2025 Aug;32(8):5784-5794. doi: 10.1245/s10434-025-17517-0. Epub 2025 May 30. Ann Surg Oncol. 2025. PMID: 40445508
Cited by
-
Editorial: New frontiers in pancreatic cancer care: Multidisciplinary approaches, the role of Pancreas Units, and their organizational impacts.Front Surg. 2023 Mar 23;10:1182206. doi: 10.3389/fsurg.2023.1182206. eCollection 2023. Front Surg. 2023. PMID: 37035562 Free PMC article. No abstract available.
-
Efficacy and safety of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in patients with pancreatic cancer peritoneal metastasis.World J Surg Oncol. 2024 Sep 2;22(1):212. doi: 10.1186/s12957-024-03464-9. World J Surg Oncol. 2024. PMID: 39218891 Free PMC article.
-
Toward a new paradigm of care: a surgical leaders' Delphi consensus on the organizational factors of the new pancreas units (E-AHPBA PUECOF study).Updates Surg. 2024 Sep;76(5):1593-1614. doi: 10.1007/s13304-024-01839-x. Epub 2024 Apr 25. Updates Surg. 2024. PMID: 38662309 Free PMC article.
-
Malignant ascites in pancreatic cancer: Pathophysiology, diagnosis, molecular characterization, and therapeutic strategies.Front Oncol. 2023 Mar 16;13:1138759. doi: 10.3389/fonc.2023.1138759. eCollection 2023. Front Oncol. 2023. PMID: 37007072 Free PMC article. Review.
-
Co-design, co-learning, and co-production of an app for pancreatic cancer patients-the "Pancreas Plus" study protocol.Mhealth. 2023 Mar 9;9:16. doi: 10.21037/mhealth-22-48. eCollection 2023. Mhealth. 2023. PMID: 37089263 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical